000838816 000__ 05523cam\a2200529Ii\4500 000838816 001__ 838816 000838816 005__ 20230306144656.0 000838816 006__ m\\\\\o\\d\\\\\\\\ 000838816 007__ cr\un\nnnunnun 000838816 008__ 180430s2018\\\\sz\a\\\\ob\\\\001\0\eng\d 000838816 019__ $$a1033553815$$a1033661587$$a1033906083$$a1034551294$$a1038453336 000838816 020__ $$a9783319732381$$q(electronic book) 000838816 020__ $$a3319732382$$q(electronic book) 000838816 020__ $$z9783319732374 000838816 020__ $$z3319732374 000838816 0247_ $$a10.1007/978-3-319-73238-1$$2doi 000838816 035__ $$aSP(OCoLC)on1032810311 000838816 035__ $$aSP(OCoLC)1032810311$$z(OCoLC)1033553815$$z(OCoLC)1033661587$$z(OCoLC)1033906083$$z(OCoLC)1034551294$$z(OCoLC)1038453336 000838816 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dGW5XE$$dEBLCP$$dYDX$$dAZU$$dCOO$$dUPM$$dUAB$$dOCLCF$$dOCLCQ 000838816 049__ $$aISEA 000838816 050_4 $$aQR182.2.I46 000838816 08204 $$a616.0790285$$223 000838816 24500 $$aAccelerated path to cures /$$cJosep Bassaganya-Riera, editor. 000838816 264_1 $$aCham, Switzerland :$$bSpringer,$$c[2018] 000838816 300__ $$a1 online resource :$$billustrations. 000838816 336__ $$atext$$btxt$$2rdacontent 000838816 337__ $$acomputer$$bc$$2rdamedia 000838816 338__ $$aonline resource$$bcr$$2rdacarrier 000838816 347__ $$atext file$$bPDF$$2rda 000838816 504__ $$aIncludes bibliographical references and index. 000838816 5050_ $$aIntro; Contents; Contributors; Chapter 1: Introduction to Accelerated Path to Cures and Precision Medicine in Inflammatory Bowel Disease; Overview; LANCL2 Drug Development Use Case; Network Modeling for PD Biomarker Analyses Use Case; References; Chapter 2: Computer-Aided Drug Discovery; Overview; Structure-Based Versus Ligand-Based Modeling; Ligand-Based Modeling Approaches; Similarity Searching; Ligand-Based Pharmacophore Modeling; Quantitative-Structure Activity Relationship Modeling (QSAR); Structure-Based Modeling Approaches; Molecular Docking; Structure-Based Pharmacophore Modeling 000838816 5058_ $$aMolecular Docking and Virtual ScreeningMolecular Docking; Virtual Screening; Application of Molecular Dynamics Simulations in Drug Discovery; General Considerations; Applications of Molecular Dynamics in Generating Conformational Ensembles; MD and Scoring; MD to Discover Novel Binding Sites; Success Stories in Computational Drug Discovery; Concluding Remarks; References; Chapter 3: Preclinical Studies: Efficacy and Safety; Preclinical Studies: Safety; Preclinical Studies: Efficacy; Animal Models of IBD to Test Therapeutic Efficacy; DSS-Induced Colitis; Adoptive Transfer Model of Colitis 000838816 5058_ $$aCitrobacter rodentium Infection Model of ColitisMDR1a−/− Model of Colitis; Pig as Model of Colitis; Cell-Specific Knockout Mice; Animal Models Used in Drug Development for IBD; Utilization of Computational Models in Preclinical Studies; Concluding Remarks; References; Chapter 4: From Nutritional Immunology to Drug Development; Overview; Nutritional Modulation of Immune-Mediated Diseases; Important Immunometabolic Pathways; Nutrition-Based Therapeutics Used to Treat Gastrointestinal Diseases; Computational Approaches to Discover New Therapeutics: A Precision Medicine Initiative 000838816 5058_ $$aAccelerating the Path to Precision MedicineComputational Models Used for Precision Medicine Discovery Measures Endpoints of Immune Mediated and Inflammatory Diseases; Concluding Remarks; References; Chapter 5: Development of Synthetic Patient Populations and In Silico Clinical Trials; Overview; Clinical Research and Clinical Trials; Design Strategies; Data Sources; Predictive Modeling for Precision Medicine; Data-Driven Models; Mechanistic Models; Rule-Based Models; Human Avatars: Virtual Patient Populations; Treatment Design; Data-Driven Design; Mechanistic Modeling-Based Design 000838816 5058_ $$aStatistical AnalysisDimensionality Reduction; Analysis of Variance; Concluding Remarks; References; Index 000838816 506__ $$aAccess limited to authorized users. 000838816 520__ $$aAccelerated Path to Cures provides a transformative perspective on the power of combining advanced computational technologies, modeling, bioinformatics and machine learning approaches with nonclinical and clinical experimentation to accelerate drug development. This book discusses the application of advanced modeling technologies, from target identification and validation to nonclinical studies in animals to Phase 1-3 human clinical trials and post-approval monitoring, as alternative models of drug development. As a case of successful integration of computational modeling and drug development, we discuss the development of oral small molecule therapeutics for inflammatory bowel disease, from the application of docking studies to screening new chemical entities to the development of next-generation in silico human clinical trials from large-scale clinical data. Additionally, this book illustrates how modeling techniques, machine learning, and informatics can be utilized effectively at each stage of drug development to advance the progress towards predictive, preventive, personalized, precision medicine, and thus provide a successful framework for Path to Cures. . 000838816 588__ $$aOnline resource; title from PDF title page (viewed May 02, 2018). 000838816 650_0 $$aImmunology. 000838816 650_0 $$aImmunoinformatics. 000838816 650_0 $$aDrug development. 000838816 7001_ $$aBassaganya-Riera, Josep,$$eeditor. 000838816 77608 $$iPrint version: $$z3319732374$$z9783319732374$$w(OCoLC)1013730941 000838816 852__ $$bebk 000838816 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-73238-1$$zOnline Access$$91397441.1 000838816 909CO $$ooai:library.usi.edu:838816$$pGLOBAL_SET 000838816 980__ $$aEBOOK 000838816 980__ $$aBIB 000838816 982__ $$aEbook 000838816 983__ $$aOnline 000838816 994__ $$a92$$bISE